EUVIMEDEUVIMED entdecken
Crossref

lncTIMP3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis

Taxi Wumiti, Lining Wang, Bin Xu, Yong Ma, Yihua Zhu, Xinchen Zuo, Weiqing Qian, Xudong Chu, Haitao Sun

Molecular Biology Reports · 2024-12 · 51 (1)

DOI: 10.1007/s11033-024-09652-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, online erschienen am 01.06.2024. Verfasst von Taxi Wumiti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of New Techniques of Restoration & Reconstruction, Institute of Traumatology & Orthopedics, Nanjing University of Chinese Medicine, Nanjin…. Hauptthemen laut MEDLINE: Cell Differentiation, Mesenchymal Stem Cells, MicroRNAs, Osteogenesis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: The Science and Technology Project Plan of Wuxi Administration of Traditional Chinese Medicine, Wuxi Science and Technology Bureau Science and Technology Research Project, Top Talent Support Program for young and middle-aged people of Wuxi Health Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Promoting the balance between bone formation and bone resorption is the main therapeutic goal for postmenopausal osteoporosis (PMOP), and bone marrow mesenchymal stem cells (BMSCs) osteogenic differentiation plays an important regulatory role in this process. Recently, several long non-coding RNAs (lncRNAs) have been reported to play an important regulatory role in the occurrence and development of OP and participates in a variety of physiological and pathological processes. However, the role of lncRNA tissue inhibitor of metalloproteinases 3 (lncTIMP3) remains to be investigated. METHODS: The characteristics of BMSCs isolated from the PMOP rat model were verified by flow cytometry assay, alkaline phosphatase (ALP), alizarin red and Oil Red O staining assays. Micro-CT and HE staining assays were performed to examine histological changes of the vertebral trabeculae of the rats. RT-qPCR and western blotting assays were carried out to measure the RNA and protein expression levels. The subcellular location of lncTIMP3 was analyzed by FISH assay. The targeting relationships were verified by luciferase reporter assay and RNA pull-down assay. RESULTS: The trabecular spacing was increased in the PMOP rats, while ALP activity and the expression levels of Runx2, Col1a1 and Ocn were all markedly decreased. Among the RNA sequencing results of the clinical samples, lncTIMP3 was the most downregulated differentially expressed lncRNA, also its level was significantly reduced in the OVX rats. Knockdown of lncTIMP3 inhibited osteogenesis of BMSCs, whereas overexpression of lncTIMP3 exhibited the reverse results. Subsequently, lncTIMP3 was confirmed to be located in the cytoplasm of BMSCs, implying its potential as a competing endogenous RNA for miRNAs. Finally, the negative targeting correlations of miR-214 between lncTIMP3 and Smad4 were elucidated in vitro. CONCLUSION: lncTIMP3 may delay the progress of PMOP by promoting the activity of BMSC, the level of osteogenic differentiation marker gene and the formation of calcium nodules by acting on the miR-214/Smad4 axis. This finding may offer valuable insights into the possible management of PMOP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell DifferentiationMesenchymal Stem CellsMicroRNAsOsteogenesisOsteoporosis, PostmenopausalRNA, Long NoncodingSmad4 ProteinAnimalsFemaleHumansRatsBone Marrow CellsDisease Models, AnimalRats, Sprague-DawleyTissue Inhibitor of Metalloproteinase-3

Stichwörter der Autor:innen

Bone marrow mesenchymal stem cells (BMSCs)Osteogenic differentiationPostmenopausal osteoporosisSmad4lncTIMP3

Substanzen

MicroRNAsMirn214 microRNA, ratRNA, Long NoncodingSmad4 ProteinTissue Inhibitor of Metalloproteinase-3

Autor:innen und Institutionen

  • Laboratory of New Techniques of Restoration & Reconstruction, Institute of Traumatology & Orthopedics, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
  • School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
  • Chinese Medicine Centre (International Collaboration between Western Sydney University, Beijing University of Chinese Medicine), Western Sydney University, Sydney, Australia.
  • Department of Orthopedic Surgery, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People's Hospital, Wuxi, 214187, Jiangsu, China.
  • Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint Disease, Wuxi TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Wuxi, 214000, Jiangsu, China.
  • Department of Orthopedics, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, Jiangsu, China.

Förderung

  • The Science and Technology Project Plan of Wuxi Administration of Traditional Chinese Medicine
  • Wuxi Science and Technology Bureau Science and Technology Research Project
  • Top Talent Support Program for young and middle-aged people of Wuxi Health Committee

Zitieren

APA

Wumiti, T., Wang, L., Xu, B., Ma, Y., Zhu, Y., Zuo, X., Qian, W., Chu, X., & Sun, H. (2024). lncTIMP3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis. Molecular Biology Reports, 51(1). https://doi.org/10.1007/s11033-024-09652-w

Vancouver

Wumiti T, Wang L, Xu B, Ma Y, Zhu Y, Zuo X, et al. lncTIMP3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis. Molecular Biology Reports. 2024;51(1). doi:10.1007/s11033-024-09652-w

BibTeX
@article{Wumiti2024,
  author = {Wumiti, Taxi and Wang, Lining and Xu, Bin and Ma, Yong and Zhu, Yihua and Zuo, Xinchen and Qian, Weiqing and Chu, Xudong and Sun, Haitao},
  title = {lncTIMP3 promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-214/Smad4 axis to relieve postmenopausal osteoporosis},
  journal = {Molecular Biology Reports},
  year = {2024},
  volume = {51},
  number = {1},
  doi = {10.1007/s11033-024-09652-w}
}
Kostenlos starten →